Role of the angiotensin II type-2 receptor in radiation nephropathy

被引:20
作者
Cohen, Eric P.
Fish, Brian L.
Sharma, Mukut
Li, X. Allen
Moulder, John E.
机构
[1] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA
关键词
D O I
10.1016/j.trsl.2007.03.004
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Experimental studies have shown that blockade of the angiotensin II type- 1 (AT(1)) receptor is effective in the mitigation and treatment of radiation -induced chronic renal failure. Also, blockade of the angiotensin II type-2 (AT(2)) receptor with PD- 123319 also had a modest, but reproducible, beneficial effect in experimental radiation nephropathy, and it might augment the efficacy of an AT, blocker (L- 158,809). Those studies could not exclude the possibility that the effects of AT(2) blockade were nonspecific. The current studies confirm the efficacy of AT(2) blockade for mitigation of experimental radiation nephropathy but paradoxically find no detectable level of AT(2) receptor binding in renal membranes. However, the results of a bioassay showed that the circulating levels of the AT(2) blocker were orders-of -magnitude too low to block AT, receptors. The effect of AT(2) blockade in radiation nephropathy cannot be explained by binding to the AT, receptor, and the efficacy of the AT, blockade in the same model cannot be explained by unopposed overstimulation of the AT(2) receptor.
引用
收藏
页码:106 / 115
页数:10
相关论文
共 43 条
[1]   Angiotensin II type AT2 receptor mRNA expression and renal vasodilatation are increased in renal failure [J].
Bautista, R ;
Sánchez, A ;
Hernández, J ;
Oyekan, A ;
Escalante, B .
HYPERTENSION, 2001, 38 (03) :669-673
[2]   ANGIOTENSIN-II RECEPTOR SUBTYPES - CHARACTERIZATION, SIGNALING MECHANISMS, AND POSSIBLE PHYSIOLOGICAL IMPLICATIONS [J].
BOTTARI, SP ;
DEGASPARO, M ;
STECKELINGS, UM ;
LEVENS, NR .
FRONTIERS IN NEUROENDOCRINOLOGY, 1993, 14 (02) :123-171
[3]   Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo [J].
Brown, NJ ;
Nakamura, S ;
Ma, LJ ;
Nakamura, I ;
Donnert, E ;
Freeman, M ;
Vaughan, DE ;
Fogo, AB .
KIDNEY INTERNATIONAL, 2000, 58 (03) :1219-1227
[4]   Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury [J].
Cao, ZM ;
Bonnet, F ;
Candido, R ;
Nesteroff, SP ;
Burns, WC ;
Kawachi, H ;
Shimizu, F ;
Carey, RM ;
De Gasparo, M ;
Cooper, ME .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (07) :1773-1787
[5]  
CHANG RSL, 1992, J PHARMACOL EXP THER, V262, P133
[6]   Successful brief captopril treatment in experimental radiation nephropathy [J].
Cohen, EP ;
Fish, BL ;
Moulder, JE .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1997, 129 (05) :536-547
[7]   Angiotensin II infusion exacerbates radiation nephropathy [J].
Cohen, EP ;
Fish, BL ;
Moulder, JE .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1999, 134 (03) :283-291
[8]   Radiation nephropathy [J].
Cohen, EP ;
Robbins, MEC .
SEMINARS IN NEPHROLOGY, 2003, 23 (05) :486-499
[9]   Successful treatment of radiation nephropathy with angiotensin II blockade [J].
Cohen, EP ;
Hussain, S ;
Moulder, JE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 55 (01) :190-193
[10]   The renin-angiotensin system in experimental radiation nephropathy [J].
Cohen, EP ;
Fish, BL ;
Moulder, JE .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2002, 139 (04) :251-257